-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Proxalutamide
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1398046-21-3.gif)
| Category | SARS-CoV |
| CAS | 1398046-21-3 |
| Description | Proxalutamide is a non-steroidal androgen receptor (AR) antagonist with potential anti-tumor activity for the treatment of prostate cancer and breast cancer. |
Product Information
| Synonyms | GT 0918; pruxelutamide; Benzonitrile, 4-[4,4-dimethyl-3-[6-[3-(2-oxazolyl)propyl]-3-pyridinyl]-5-oxo-2-thioxo-1-imidazolidinyl]-3-fluoro-2-(trifluoromethyl)- |
| IUPAC Name | 4-[4,4-dimethyl-3-[6-[3-(1,3-oxazol-2-yl)propyl]pyridin-3-yl]-5-oxo-2-sulfanylideneimidazolidin-1-yl]-3-fluoro-2-(trifluoromethyl)benzonitrile |
| Molecular Weight | 517.5 |
| Molecular Formula | C24H19F4N5O2S |
| Canonical SMILES | CC1(C(=O)N(C(=S)N1C2=CN=C(C=C2)CCCC3=NC=CO3)C4=C(C(=C(C=C4)C#N)C(F)(F)F)F)C |
| InChI | InChI=1S/C24H19F4N5O2S/c1-23(2)21(34)32(17-9-6-14(12-29)19(20(17)25)24(26,27)28)22(36)33(23)16-8-7-15(31-13-16)4-3-5-18-30-10-11-35-18/h6-11,13H,3-5H2,1-2H3 |
| InChIKey | KCBJGVDOSBKVKP-UHFFFAOYSA-N |
| Boiling Point | 615.9±65.0 °C at 760 mmHg |
| Purity | 98.79% |
| Density | 1.48±0.1 g/cm3(Predicted) |
| Solubility | Soluble in DMSO |
| Appearance | Solid Powder |
| Storage | Store at -20°C |
| Complexity | 894 |
| Exact Mass | 517.11955869 |
| In Vitro | Proxalutamide (GT0918) down-regulates AR protein level in prostate cancer cells. Proxalutamide can overcome the resistance of prostatic cancer cells by downregulating the expression of AR genes Proxalutamide (GT0918, 0-200 μM) dose-dependently inhibits cell viability in LNCaP and 22RV1. |
| In Vivo | The elimination half-life (t1/2) of proxalutamide in rats is approximately 2 h regardless of whether it is administered by the intragastric or the intravenous route. The maximum plasma concentration of proxalutamide (Cmax) could reach 2 μg/mL or higher, and the oral absolute bioavailability (F) was approximately 80%. |
| Target | Androgen Receptor; SARS-CoV |
| XLogP3-AA | 4.3 |
